P0752 Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study
- DOI
- 10.1093/ecco-jcc/jjae190.0926
- Published
- 2025-01
- Container
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1093/ecco-jcc/jjae190.0926,
title = {P0752 Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study},
author = {A Hart and I Blumenstein and T Kobayashi and M Chaparro and M C Fantini and M Fumery and A Keohane and E Dhesi and T Tian and I Redondo and E L Barnes},
year = {2025},
journal = {Journal of Crohn's and Colitis},
doi = {10.1093/ecco-jcc/jjae190.0926},
url = {https://doi.org/10.1093/ecco-jcc/jjae190.0926}
}RIS
TY - JOUR TI - P0752 Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study AU - A Hart AU - I Blumenstein AU - T Kobayashi AU - M Chaparro AU - M C Fantini AU - M Fumery AU - A Keohane AU - E Dhesi AU - T Tian AU - I Redondo AU - E L Barnes PY - 2025 JO - Journal of Crohn's and Colitis DO - 10.1093/ecco-jcc/jjae190.0926 UR - https://doi.org/10.1093/ecco-jcc/jjae190.0926 ER -
APA
Hart, A., Blumenstein, I., Kobayashi, T., Chaparro, M., Fantini, M. C., Fumery, M., Keohane, A., Dhesi, E., Tian, T., Redondo, I., & Barnes, E. L. (2025). P0752 Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjae190.0926
Source records
- crossref · retrieved 2026-09-27T07:53:42.244Z